HélÃ"ne Haguet

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3891184/publications.pdf

Version: 2024-02-01

1163117 1058476 14 334 8 14 citations g-index h-index papers 14 14 14 604 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Association Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall Survival. JAMA Oncology, 2016, 2, 625.	7.1	158
2	Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis. Expert Opinion on Drug Safety, 2017, 16, 5-12.	2.4	48
3	Validation and standardization of the ETP-based activated protein C resistance test for the clinical investigation of steroid contraceptives in women: an unmet clinical and regulatory need. Clinical Chemistry and Laboratory Medicine, 2020, 58, 294-305.	2.3	30
4	Procoagulant activity of extracellular vesicles as a potential biomarker for risk of thrombosis and DIC in patients with acute leukaemia. Journal of Thrombosis and Thrombolysis, 2017, 43, 224-232.	2.1	21
5	BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis?. TH Open, 2018, 02, e68-e88.	1.4	21
6	The Risk of Arterial Thrombosis in Patients With Chronic Myeloid Leukemia Treated With Second and Third Generation BCR-ABL Tyrosine Kinase Inhibitors May Be Explained by Their Impact on Endothelial Cells: An In-Vitro Study. Frontiers in Pharmacology, 2020, 11, 1007.	3.5	16
7	Impact of functional inorganic nanotubes f-INTs-WS2 on hemolysis, platelet function and coagulation. Nano Convergence, 2018, 5, 31.	12.1	11
8	Long-Term Survival, Vascular Occlusive Events and Efficacy Biomarkers of First-Line Treatment of CML: A Meta-Analysis. Cancers, 2020, 12, 1242.	3.7	9
9	Clinical performance of the Panbio assay for the detection of SARSâ€CoVâ€2 IgM and IgG in COVIDâ€19 patients. Journal of Medical Virology, 2021, 93, 3277-3281.	5.0	7
10	Multiple Causes of Cardiotoxic Effects in Patients With Chronic Myeloid Leukemiaâ€"Reply. JAMA Oncology, 2016, 2, 829.	7.1	4
11	BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Systematic Review and Meta-Analysis on the Risk of Cardiovascular Events, Major Molecular Response and Overall Survival. Blood, 2015, 126, 2785-2785.	1.4	4
12	Assessment of acquired activated protein C resistance with the FibWave and comparison with the ETPâ€based APC resistance. International Journal of Laboratory Hematology, 2021, 43, 802-812.	1.3	3
13	Characterization of core/shell Cu/Ag nanopowders synthesized by electrochemistry and assessment of their impact on hemolysis, platelet aggregation, and coagulation on human blood for potential wound dressing use. Journal of Nanoparticle Research, 2017, 19, 1.	1.9	1
14	The edoxabanâ€M4 metabolite and measurement of edoxaban by chromogenic assays in human plasma. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12680.	2.3	1